This trial is evaluating whether Acalabrutinib will improve 1 primary outcome, 3 secondary outcomes, and 5 other outcomes in patients with Leukemia, Lymphoid. Measurement will happen over the course of From the start of study treatment to safety follow-up period (approximately 30 days from last dose).
This trial requires 553 total participants across 1 different treatment group
This trial involves a single treatment. Acalabrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Leukemia develops from genetic mutations in early blood cells as well as exposure to environmental toxins, with the two categories of exposures being the most powerful factors. The most likely cause for any type of leukemia is a combination of these two forces. Genetic mutations can take place at any time during development and may result in different types of leukemia. The mechanism of leukemogenesis is complex and still poorly understood." - Anonymous Online Contributor
"This list is representative of many forms of cancer and its treatments. Although some cancer is curable at diagnosis, most forms of cancer, whether cancer of the bone, breast, brain, brainstem, liver, ovarian, colon, pancreas, prostate, or testis, have no cure." - Anonymous Online Contributor
"The most important signs of cancer are the symptoms, which include the usual pain and mass, itching, bleeding, and skin rashes. Cancer must come to your attention before these signs have set in and the disease can no longer be treated. If there are no symptoms, a dentist could be the first person you turn to as you try to find the first sign" - Anonymous Online Contributor
"Leukemogenesis is the process in which a normal, healthy person is transformed into a cancerous one by mutation or environmental exposure to a carcinogen. Leukaemias and other cancers are all associated with the presence of a mutation in one of the cancer-causing genes. The majority of leukaemias and lymphomas occur on the bone marrow." - Anonymous Online Contributor
"It is difficult to cure a leukemia (in particular AML due to its high level of resistance to conventional chemotherapy). However, with improved knowledge, strategies have been developed that are potentially effective in AML." - Anonymous Online Contributor
"The current US estimates may be as low as 7,926/year. If the current estimates are accurate, this might require a screening program to detect disease at an early stage." - Anonymous Online Contributor
"Ibrutinib is FDA approved for use in mantle cell lymphoma (since 2013) and (after FDA approval in 2017) a rare form of chronic lymphocytic leukemia also called mantle cell lymphoma." - Anonymous Online Contributor
"Most pediatric patients are in good or very good spirits after treatment (chemo therapy) due to their good prognosis. But most parents, who are usually not able to come to see their child because of their busy work, go through an awful ordeal: the fear of their child's prognosis, the stress and the hope of getting cured but not dying from leukemia. This is what people need to understand to avoid bad attitudes towards doctors, patients and the whole medical field of treatment and cure." - Anonymous Online Contributor
"Most people have a family history of leukemia or certain genetic traits. But even when these genetic risk factors are present, there are many people without leukemia. Therefore, the question of whether or not someone has leukemia is best phrased as 'how likely is this person to develop leukemia?" - Anonymous Online Contributor
"Approximately 59% of leukemia cases diagnosed in the country of Spain are reported in patients aged 50 years or older. This may reflect the increased number and severity of hematological malignancies in this population, which requires early diagnostic interventions (e.g., screening programs, improved treatment regimens, and earlier detection of these disorders)." - Anonymous Online Contributor
"In patients with solid tumors, treatment-related pain is commonly reported as an adverse event. The use of acalabrutinib is associated with significant improvement in pain, and may be a reasonable adjunct for patients with pain from solid tumors. This trial was registered at clinicaltrials.gov as NCT01319307." - Anonymous Online Contributor
"Results from a recent clinical trial of chemotherapeutic and immuno-therapeutic agents for treating patients with Acute Myeloid Leukemias (AML) and Chronic Myeloid Leukemias (CML) over this period is not as much as expected especially with the advances in treatment techniques especially using the new drugs and the drug combinations. Oncologists should be aware of the advances in treatments in CML and AML especially when looking forward for future development of drugs that is specific to either the diseases." - Anonymous Online Contributor